• Previous work had found that the denervated muscles were more responsive to the cytokine TWEAK, and the same group now reports that the scaffold and ubiquitin ligase TRAF6 is involved in the activation of various signaling molecules implicated in muscle atrophy, including c-Jun N-terminal kinase (JNK), p38 mitogen-activated protein kinase (p38 MAPK), AMP-activated protein kinase (AMPK), and nuclear factor κB (NF-κB). (sciencemag.org)
  • In response to denervation or the model of cancer-induced cachexia, TRAF6-depleted muscles also showed significantly less or no transcriptional induction of genes encoding two ubiquitin ligases implicated in muscle atrophy, as well as of genes encoding proteins involved in autophagy. (sciencemag.org)
  • There is an active NIH supported MSA atrophy base of clinical trials available at the NIH and through the NINDS (National Institute of Neurological Disorders and Stroke), as well as through independent centers around the United States and Canada. (newsmax.com)
  • Posterior cortical atrophy (PCA) refers to gradual and progressive degeneration of the outer layer of the brain (the cortex) in the part of the brain located in the back of the head (posterior). (alz.org)
  • With no FDA-approved therapies yet for the treatment of geographic atrophy (GA), some companies and institutions, eager to change that fact, are initiating or resurrecting past research approaches to discern effective methods of combating this advanced form of dry AMD. (wabi.tv)
  • During atrophy, there is a down-regulation of protein synthesis pathways, and an activation of protein degradation. (wikipedia.org)
  • Finally, the activation of NF-κB in TRAF6-knockout mouse embryo fibroblasts by TWEAK was mostly abolished, which suggests that TRAF6 is likely to link this atrophy-inducing cytokine to downstream signaling pathways. (sciencemag.org)
  • Almost a decade ago, Allergan (Dublin) began to study its glaucoma drug brimonidine (now known as Alphagan) as a potential treatment for Geographic Atrophy because it had demonstrated neuroprotective qualities in the company's animal studies. (wabi.tv)
  • With symptoms such as dryness, burning, or itching of the vagina, vulvovaginal atrophy is estimated to affect up to 98% of postmenopausal women, many of whom will fail to report symptoms to their healthcare providers or seek help. (news-medical.net)